Defense World
07 Feb 2026, 09:46 UTC · 39w ago
Impact · against what's priced in
The consensus 'Moderate Buy' rating for DiaMedica Therapeutics provides a positive signal of analyst confidence. However, as a lagging indicator based on existing research, it offers limited catalyst potential for a significant price move.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish
DiaMedica Therapeutics (DMAC) has a consensus rating of 'Moderate Buy' from six research firms.
More positive than 64% of claims this week
Five out of six analysts covering DMAC have given the stock a buy recommendation.
Continue reading
5 related stories
Five out of six analysts covering the company have issued buy recommendations, suggesting a strong professional consensus on the stock's upside.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 52% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
The company has a consensus 'Moderate Buy' rating with five buy recommendations versus one sell.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
+11.1%
Price agrees with the score
$9.04 vs $8.14 close before publication (Feb 6) · not market-adjusted
DMAC chart →
